The present invention provides compounds that block the NCCa-ATP channel for use in (a) the prevention or treatment of neural cell swelling in the brain of a subject; (b) the alleviation of the negative effects of traumatic brain injury or cerebral ischemia stemming from neural cell swelling in a subject; (c) treating a subject having central or peripheral nervous system damage; or (d) treating a subject having bleeding in the brain.